Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study
Martin Dietrich, MD, PhD and Roy Herbst, MD discuss how the evolving first-line treatment options for EGFR-mutated non-small cell lung cancer, including osimertinib monotherapy, osimertinib plus chemotherapy, and amivantamab plus lazertinib, have reshaped the landscape, with a strong emphasis on overall survival benefits and the role of combination therapies in improving patient outcomes.
EP. 1: Brief Overview of Current Treatment Landscape for 1L EGFRm NSCLC
April 11th 2025Panelists discuss how the treatment landscape for EGFR-mutated lung cancer has evolved with 3 strong options now available, including single-agent osimertinib and 2 combinations: osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA), with the latter showing significant overall survival (OS) benefits.
EP. 2: Impressions of MARIPOSA Overall Survival and Potential Impact in Current SoC
April 11th 2025Panelists discuss how the significant overall survival (OS) benefit demonstrated by the new combination therapy (mivantamab-lazertinib) compared with standard monotherapy makes it a preferred treatment option for most patients despite a slightly increased toxicity and time commitment.
